Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06881836 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 96 → 80 locations Enrollment target: estimated 240 to confirmed 260 · Primary completion date changed from estimate of Jul 2026 to Jul 31, 2026 · Completion date: Aug 2026 to Sep 1, 2026v10 Show 3 more changesShow less
    • Enrollment target: estimated 240 to confirmed 260
    • Primary completion date changed from estimate of Jul 2026 to Jul 31, 2026
    • Completion date: Aug 2026 to Sep 1, 2026
  2. Changed Sponsor changed: Ono Pharmaceutical Co. Ltd to Ono Pharmaceutical Co., Ltd.
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 102 to 96v9 Show 1 more changeShow less
    • Study sites: 102 to 96
  4. Study sites: 103 to 102v8
  5. Study sites: 102 to 103v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 50 to 102v6
  2. Study sites: 39 to 50v5
  3. Study sites: 24 to 39v4
  4. Study sites: 12 to 24v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 5 to 12 · Start date changed from estimate of Mar 2025 to Apr 24, 2025v2 Show 2 more changesShow less
    • Study sites: 5 to 12
    • Start date changed from estimate of Mar 2025 to Apr 24, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Trial Details
NCT Number NCT06881836
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Alzheimer Disease
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov